Kite Pharma Inc (KITE) was Initiated by H.C. Wainwright to “Buy” and the brokerage firm has set the Price Target at $78. H.C. Wainwright advised their investors in a research report released on Nov 21, 2016.
Many Wall Street Analysts have commented on Kite Pharma Inc. H.C. Wainwright Initiated Kite Pharma Inc on Nov 21, 2016 to “Buy”, Price Target of the shares are set at $78.
On the company’s financial health, Kite Pharma Inc reported $-1.10 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Nov 9, 2016. Analyst had a consensus of $-1.08. The company had revenue of $7.30 million for the quarter, compared to analysts expectations of $4.90 million. The company’s revenue was up 43.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.38 EPS.
Kite Pharma Inc opened for trading at $50.6 and hit $52.14 on the upside on Monday, eventually ending the session at $51.8, with a gain of 2.45% or 1.24 points. The heightened volatility saw the trading volume jump to 8,04,164 shares. Company has a market cap of $2,584 M.
In a different news, on Nov 14, 2016, Cynthia M Butitta (Chief Operating Officer) sold 10,000 shares at $50.94 per share price. According to the SEC, on Nov 14, 2016, Jeffrey Wiezorek (SVP Clinical Development) sold 1,500 shares at $50.18 per share price. On Aug 16, 2016, Helen Susan Kim (EVP, Business Development) sold 35,900 shares at $61.54 per share price, according to the Form-4 filing with the securities and exchange commission.
Kite Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company does this using its engineered autologous cell therapy (eACT) which is an approach to the treatment of cancer. eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). It is conducting a Phase II clinical trial of a TCR-based therapy and multiple Phase I-IIa clinical trials of CAR- and TCR-based therapies. The Company’s lead product candidate KTE-C19 is a CAR-based therapy for the treatment of refractory diffuse large B cell lymphoma (DLBCL) primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is developing a pipeline of eACT-based product candidates for the treatment of advanced solid and hematological malignancies: CD19CAR KTE-C19CAR and EGFRvlll CAR among others.